AI, particularly AlphaFold, is revolutionizing drug discovery by predicting protein structures and accelerating the development of new medicines. A recent study utilized AlphaFold to identify a potential drug for liver cancer, specifically hepatocellular carcinoma (HCC). The study combined AlphaFold with AI platforms like PandaOmics and Chemistry42 to discover a potent inhibitor for CDK20, a protein associated with HCC. HCC is a major global health concern, and the use of AI platforms like PandaOmics has helped identify potential therapeutic targets for this form of liver cancer.

CDK20, also known as CCRK, is overexpressed in various cancers, including HCC, making it a valuable target for cancer treatment. Leveraging AI platforms like Chemistry42 and AlphaFold, researchers have been able to develop novel inhibitors for CDK20, demonstrating the effectiveness of AI in drug discovery.

The integration of AlphaFold’s predictions into the Pharma.AI platform has led to the rapid identification and optimization of CDK20 inhibitors. Through an AI-driven approach, researchers were able to synthesize a hit molecule for HCC within a short timeframe, showcasing the transformative impact of AI on drug discovery processes.

Overall, AI, particularly AlphaFold, is playing a crucial role in accelerating drug discovery efforts, reducing time and cost constraints, and opening up new possibilities for the development of targeted therapeutic agents for diseases like liver cancer.

Source link

Source link: https://www.marktechpost.com/2024/06/29/leveraging-alphafold-and-ai-for-rapid-discovery-of-targeted-treatments-for-liver-cancer/?amp